5326122026-04-012026-06-305326122026-04-012026-06-30in-capmkt:OtherExpenses1Member5326122026-04-012026-06-30in-capmkt:OtherExpenses2Member5326122026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532612INDOCONOTLISTEDINE873D01024INDOCO REMEDIES LIMITEDMain BoardEquity2026-04-012027-03-312026-07-282026-07-15INRLakhsQuarterlyFirst quarterSingle segmentPHARMACEUTICALS2026-07-2810:45:002026-07-2811:45:00Not applicable2026-04-012026-06-30UnauditedConsolidated46750000002180000046968000001045800000398900000135800000101410000028290000034530000016702000004893000000-196200000973400000777200000105900000169000001228000000654400000000065440000068000006612000006499000004500000656700000450000018460000027.097.09007.097.091. The unaudited Consolidated Results for the Quarter ended 30th June, 2026, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 28th July, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. <br /> <br /> 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. <br /> <br /> 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. <br /> <br /> 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: <br /> <br /> (Rs. in Lakhs) <br /> Net Sales Qtr ended Qtr ended Qtr ended Year ended <br /> & Income 30-06-2026 31-03-2026 30-06-2025 31-03-2026 <br /> from Operations (Unaudited) (Audited) (Unaudited) (Audited) <br /> <br /> India 31,177 24,714 27,783 1,12,412 <br /> Outside India 15,445 20,876 15,303 66,882 --------------------------------------------------------------------------------------------------------------------------- <br /> Total : 46,622 45,590 43,086 1,79,294============================================================== <br /> <br /> 5. The Consolidated Financial Results includes the results of the following companies. <br /> ----------------------------------------------------------------------------------------------------------------------------- <br /> Name of the Company % of shareholding Consolidated as <br /> ------------------------------------------------------------------------------------------------------------------------------ <br /> XTEND INDUSTRIAL DESIGNERS 100.00 SUBSIDIARY <br /> & ENGINEERS PVT LTD <br /> INDOCO REMEDIES CZECH SRO 100.00 SUBSIDIARY <br /> INDOCO REMEDIES UK LTD 100.00 SUBSIDIARY <br /> WARREN REMEDIES PVT LTD 100.00 SUBSIDIARY <br /> FPP HOLDING COMPANY, LLC 85.00 SUBSIDIARY <br /> -------------------------------------------------------------------------------------------------------------------------- <br /> <br /> 6. Figures for the quarter ended 31.3.2026 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2025 (limited reviewed). <br /> <br /> 7. (*) The Company completed the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. The gain on sale of Rs 9,734 Lakhs has been recognized as an Exceptional Item in the Statement of Profit or Loss. <br /> RESEARCH & DEVELOPMENT EXPENSES185400000OTHER EXPENSES1484800000Items that will not be reclassified to profit & loss-6200000-6200000-1500000Items that may be reclassified to profit or loss11800000118000003000006800000